These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 23575073)
1. Morphological profile and receptor status in breast carcinoma: an institutional study. Rao C; Shetty J; Kishan Prasad HL J Cancer Res Ther; 2013; 9(1):44-9. PubMed ID: 23575073 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status--a study in a tertiary care centre. Chakrabarti S; Karmakar R; Barui G; Maity PK; Bandyopadhyay A; Roy A J Indian Med Assoc; 2012 Dec; 110(12):876-9. PubMed ID: 23936949 [TBL] [Abstract][Full Text] [Related]
3. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
4. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
5. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Arafah M Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430 [TBL] [Abstract][Full Text] [Related]
6. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737 [TBL] [Abstract][Full Text] [Related]
7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Tsutsumi Y Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930 [TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression]. Fan Y; Guan Y; Zhao WH; Li Q; Xu BH Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993 [TBL] [Abstract][Full Text] [Related]
9. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047 [TBL] [Abstract][Full Text] [Related]
10. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand. Shahi KS; Bhandari G; Singh A J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737 [TBL] [Abstract][Full Text] [Related]
11. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein. Recăreanu F; Simionescu C; Georgescu CV; Pirici E Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825 [TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696 [TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma. El-Hafez AA; El Aaty Shawky A; Hasan B Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005 [TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. Ravikumar G; Ananthamurthy A J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355 [TBL] [Abstract][Full Text] [Related]
16. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339 [TBL] [Abstract][Full Text] [Related]
17. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272 [TBL] [Abstract][Full Text] [Related]
18. [Expression of Ki67 and clinicopathological features in breast cancer]. Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913 [TBL] [Abstract][Full Text] [Related]
19. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Almasri NM; Al Hamad M Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]